Study Group: IV Remodulin Prescribers for PAH (US)(?)
Council Members in this Study Group: 34
Request a survey with this Study Group
Leading Experts in this Study Group
Robert Aris, MD
Associate Professor of Medicine
University of North Carolina Chapel Hill - CC
Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...
Robyn Barst, MDFormerDirector
New York Presbyterian & Columbia Medical Center
Robyn J Barst, MD is Professor Emeritus of Pediatrics (in Medicine) at the College of Physicians and Surgeons at Columbia University. She was Director of the New York-Presbyterian Pulmonary Hypertension Center 1982-2008. She is a Fellow of the American Academy of Pediatrics, American College of Cardiology,...
Victor Tapson, MDMedical Director of Pulmonary Hypertension Center
Duke University
Victor Tapson, MD, is Professor of Medicine in the Division of Pulmonary and Critical Care at Duke University School of Medicine and the Medical Director of the Duke Pulmonary Hypertension Center. Dr. Tapson was Director for the Duke Lung Transplant Program for over 10 years and Director for the Center...
Assistant Professor & Director
University of Florida
Kamal Mubarak, MD, is an Assistant Professor and Director of the Pulmonary Vascular Disease Program at University of Florida, Gainesville. Dr. Mubarak's clinical specialties include Internal Medicine, Critical Care Medicine, and Pulmonary Disease. He is involved in numerous clinical trials in treating...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Oral Treprostinil: An effective medicine hiding in a study with a challenging design?
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients. This is important because the definition of functional class II is that a patient has a sight...
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...
Peripheral lung nodules have been difficult for the bronchoscopist in the past to biopsy in order to identify the etiology. Using these two techniques, which requires some increased training by the interventionalist, the bronchoscopist may be able to now diagnose malignancy vs infection to help with...
United Therapeutics has had the benefit of the doubt re use of IV remodulin based on "relative convenience", despite expense and has not uniformly been adopted across PH centers and providers. Despite the small overall number of infections, the rate of the more life threatening gram negative...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director